FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3165453834> ?p ?o ?g. }

• W3165453834 abstract "Abstract Necroptosis, a regulated form of necrosis, has emerged as a novel therapeutic strategy that could enhance cancer immunotherapy. However, its role in tumorigenesis is still debated because recent studies have reported both anti- and pro-tumoral effects. Here, we aimed to systematically evaluate the associations between tumor necroptosis (mixed lineage kinase domain-like protein, MLKL; phosphorylated MLKL, pMLKL; and receptor-interacting protein kinase 1–receptor-interacting protein kinase 3, RIPK1–RIPK3 interaction) and tumor-infiltrating immune cells (CD8+ and FOXp3+ T cells and CD163+ M2 macrophages) and tumor PD-L1 by immunohistochemistry in 88 cholangiocarcinoma (CCA) patients who had undergone surgical resection. Their associations with clinicopathological characteristics, survival data, and prognosis were evaluated. MLKL was found to be an unfavorable prognostic factor ( p- value = 0.023, HR = 2.070) and was inversely correlated with a clinically favorable immune cell signature (high CD8+/high FOXp3+/low CD163+). Both pMLKL and RIPK1–RIPK3 interaction were detected in CCA primary tissues. In contrast to MLKL, pMLKL status was significantly positively correlated with a favorable immune signature (high CD8+/high FOXp3+/low CD163+) and PD-L1 expression. Patients with high pMLKL-positive staining were significantly associated with an increased abundance of CD8+ T cell intratumoral infiltration ( p -value = 0.006). Patients with high pMLKL and PD-L1 expressions had a longer overall survival (OS). The results from in vitro experiments showed that necroptosis activation in an RMCCA-1 human CCA cell line selectively promoted proinflammatory cytokine and chemokine expression. Jurkat T cells stimulated with necroptotic RMCCA-1-derived conditioned medium promoted PD-L1 expression in RMCCA-1. Our findings demonstrated the differential associations of necroptosis activation (pMLKL) and MLKL with a clinically favorable immune signature and survival rates and highlighted a novel therapeutic possibility for combining a necroptosis-based therapeutic approach with immune checkpoint inhibitors for more efficient treatment of CCA patients." @default.
• W3165453834 created "2021-06-07" @default.
• W3165453834 creator A5006094203 @default.
• W3165453834 creator A5006258604 @default.
• W3165453834 creator A5015575554 @default.
• W3165453834 creator A5027355128 @default.
• W3165453834 creator A5031815941 @default.
• W3165453834 creator A5063628886 @default.
• W3165453834 creator A5063828355 @default.
• W3165453834 creator A5068144789 @default.
• W3165453834 creator A5079425675 @default.
• W3165453834 creator A5086139902 @default.
• W3165453834 date "2021-06-03" @default.
• W3165453834 modified "2023-10-16" @default.
• W3165453834 title "Tumor necroptosis is correlated with a favorable immune cell signature and programmed death-ligand 1 expression in cholangiocarcinoma" @default.
• W3165453834 cites W1459223630 @default.
• W3165453834 cites W1527997039 @default.
• W3165453834 cites W182201473 @default.
• W3165453834 cites W1949964307 @default.
• W3165453834 cites W1966977448 @default.
• W3165453834 cites W1981128385 @default.
• W3165453834 cites W1991235944 @default.
• W3165453834 cites W1994301968 @default.
• W3165453834 cites W2003935854 @default.
• W3165453834 cites W2005501957 @default.
• W3165453834 cites W2042699075 @default.
• W3165453834 cites W2063139530 @default.
• W3165453834 cites W2091363184 @default.
• W3165453834 cites W2094396436 @default.
• W3165453834 cites W2094765239 @default.
• W3165453834 cites W2120626244 @default.
• W3165453834 cites W2124765843 @default.
• W3165453834 cites W2132161879 @default.
• W3165453834 cites W2146810078 @default.
• W3165453834 cites W2232198960 @default.
• W3165453834 cites W2292383635 @default.
• W3165453834 cites W2302357444 @default.
• W3165453834 cites W2310278114 @default.
• W3165453834 cites W2320177900 @default.
• W3165453834 cites W2327515900 @default.
• W3165453834 cites W2337387091 @default.
• W3165453834 cites W2409565356 @default.
• W3165453834 cites W2426012524 @default.
• W3165453834 cites W2480295405 @default.
• W3165453834 cites W2500484015 @default.
• W3165453834 cites W2502521711 @default.
• W3165453834 cites W2578528809 @default.
• W3165453834 cites W2585508028 @default.
• W3165453834 cites W2589651021 @default.
• W3165453834 cites W2607173021 @default.
• W3165453834 cites W2617691667 @default.
• W3165453834 cites W2619042245 @default.
• W3165453834 cites W2724720631 @default.
• W3165453834 cites W2763492611 @default.
• W3165453834 cites W2767473306 @default.
• W3165453834 cites W2796789662 @default.
• W3165453834 cites W2802975351 @default.
• W3165453834 cites W2809972762 @default.
• W3165453834 cites W2883421263 @default.
• W3165453834 cites W2888196187 @default.
• W3165453834 cites W2890271012 @default.
• W3165453834 cites W2893903398 @default.
• W3165453834 cites W2895779851 @default.
• W3165453834 cites W2947721267 @default.
• W3165453834 cites W2950635392 @default.
• W3165453834 cites W2951232582 @default.
• W3165453834 cites W2967202427 @default.
• W3165453834 cites W2971131263 @default.
• W3165453834 cites W2971912764 @default.
• W3165453834 cites W2988270385 @default.
• W3165453834 cites W2988644538 @default.
• W3165453834 cites W2997016774 @default.
• W3165453834 cites W2998919112 @default.
• W3165453834 cites W2999823243 @default.
• W3165453834 cites W3016335747 @default.
• W3165453834 cites W3137163212 @default.
• W3165453834 cites W4242587027 @default.
• W3165453834 cites W4247073213 @default.
• W3165453834 doi "https://doi.org/10.1038/s41598-021-89977-9" @default.
• W3165453834 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8175514" @default.
• W3165453834 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34083572" @default.
• W3165453834 hasPublicationYear "2021" @default.
• W3165453834 type Work @default.
• W3165453834 sameAs 3165453834 @default.
• W3165453834 citedByCount "18" @default.
• W3165453834 countsByYear W31654538342021 @default.
• W3165453834 countsByYear W31654538342022 @default.
• W3165453834 countsByYear W31654538342023 @default.
• W3165453834 crossrefType "journal-article" @default.
• W3165453834 hasAuthorship W3165453834A5006094203 @default.
• W3165453834 hasAuthorship W3165453834A5006258604 @default.
• W3165453834 hasAuthorship W3165453834A5015575554 @default.
• W3165453834 hasAuthorship W3165453834A5027355128 @default.
• W3165453834 hasAuthorship W3165453834A5031815941 @default.
• W3165453834 hasAuthorship W3165453834A5063628886 @default.
• W3165453834 hasAuthorship W3165453834A5063828355 @default.
• W3165453834 hasAuthorship W3165453834A5068144789 @default.
• W3165453834 hasAuthorship W3165453834A5079425675 @default.
• W3165453834 hasAuthorship W3165453834A5086139902 @default.
• W3165453834 hasBestOaLocation W31654538341 @default.

• next